DRG Market Assessment reports

MARKET OUTLOOK Tumor necrosis factor-alpha (TNF-α) inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) are approved for the treatment of…

MARKET OUTLOOK Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The…

The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic…

AS is a chronic inflammatory disease belonging to the group of spondyloarthritides, involving primarily the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness…

In the last ten years, TNF-α inhibitors have transformed the treatment of axial spondyloarthritis, including ankylosing spondylitis and nonradiographic axial spondyloarthritis, and have brought…

Once limited to ankylosing spondylitis (AS), the axial spondyloarthritis (AxSpA) therapy market is undergoing rapid change as the definition of the disease expands beyond those with detectable…

The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic…

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and axial skeleton, causing pain and greatly impacting quality of life. Diagnosis can be difficult,…

Currently available therapies for the treatment of Ankylosing Spondylitis (AS) target primarily the signs and symptoms of the disease; scant data exist demonstrating an impact on structural…

In a Market Dominated by Effective TNF-Alpha Inhibitors for Moderate to Severe Disease, Where Do Physicians and Payers See Viable Areas for Differentiation? Ankylosing spondylitis (AS) is a…

In a Market Dominated by Effective TNF-Alpha Inhibitors for Moderate to Severe Disease, Where Do Physicians and Payers See Viable Areas for Differentiation? Ankylosing spondylitis (AS) is a…